Clovis Oncology


Download Documentation Clovis Oncology, Inc. at the 36th Annual JP Morgan Conference Presentation
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.31 (0.53%)
Intraday High$59.36
Intraday Low$57.83
Data as of 03/16/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
03/08/18Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035
• Claims to be issued cover all commercial dosage strengths of Rubraca® • This will be the 10th Orange Book-listed patent for Rubraca BOULDER, Colo.--(BUSINESS WIRE)--Mar. 8, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims directed to high dosage strength ruc... 
Printer Friendly VersionDownload PDF
03/07/18Clovis Oncology to Present at the Barclays Global Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 7, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 8:00 AM Eastern Time. The conference will be held at the Loews Miami Beach Hotel in Miami. A live webcast of the presentation can be accessed through the investor relations section of the C... 
Printer Friendly VersionDownload PDF
02/26/18Clovis Oncology Announces 2017 Operating Results
First full year of Rubraca® (rucaparib) U.S. sales totaled $55.5M, including $17.0M for the fourth quarter of 2017, with limited third-line BRCA-mutant ovarian cancer treatment label U.S. maintenance treatment indication under review, with April 6, 2018 PDUFA date CHMP positive trend vote communicated for limited treatment indication; formal CHMP vote anticipated in March 2018 ... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.